2020
Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development
Mirza FN, Yumeen S, Lewis JM, King ALO, Kim S, Carlson KR, Umlauf S, Surovtseva YV, Foss FM, Girardi M. Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development. Journal Of Investigative Dermatology 2020, 141: 217-221. PMID: 32534802, DOI: 10.1016/j.jid.2020.05.097.Peer-Reviewed Original Research
2010
Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)
Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). Journal Of The American Academy Of Dermatology 2010, 64: 352-404. PMID: 21145619, DOI: 10.1016/j.jaad.2010.08.037.Peer-Reviewed Original ResearchMeSH KeywordsAlkylating AgentsAntibodies, MonoclonalAntineoplastic AgentsClinical Trials as TopicCombined Modality TherapyDrug Therapy, CombinationEvidence-Based MedicineHistone Deacetylase InhibitorsHumansImmunologic FactorsMethotrexateMycosis FungoidesQuality of LifeRetinoidsSezary SyndromeSkin NeoplasmsConceptsUnited States Cutaneous Lymphoma ConsortiumSézary syndromeTherapeutic optionsTreatment of SSPreventive services guidelinesCurrent treatment optionsEvidence-based medicineMechanism of actionAdjuvant treatmentMycosis fungoidesPoor prognosisCombination therapyTreatment optionsClinical trialsClinical carePromising treatmentSpecific efficacyStandardized reviewOverall efficacyStandardized criteriaTherapyService guidelinesAdverse effectsImmunopathogenesisTreatment